Navigation Links
Phase III data show efficacy/safety of iclaprim in patients with complicated skin infections
Date:10/27/2008

Reinach, Switzerland, 26 October 2008 Arpida (SWX: ARPN) today presented the combined results from two pivotal Phase III clinical trials at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/Infectious Diseases Society of America (IDSA) 46th annual meeting in Washington, DC. In these studies, intravenous iclaprim, a novel antibiotic, showed high clinical cure rates which were similar to those of the comparator drug, linezolid, in the treatment of complicated skin and skin structure infections (cSSSI) caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). In addition, iclaprim was well-tolerated with a safety profile that compared favorably to linezolid. A New Drug Application for intravenous iclaprim in cSSSI will be discussed at the meeting of the U.S. Food and Drug Administration Anti-Infective Drugs Advisory Committee on 20 November 2008.

Iclaprim, a novel antibiotic from the trusted dihydrofolate reductase (DHFR) selective inhibitor class of antibiotics, was specifically designed to address the growing need for additional treatment options to combat resistant infections including MRSA. MRSA affects more than 2 million people in the United States each year and rates of hospital- and community-acquired MRSA are on the rise. ,

"The high efficacy rates and favorable tolerability profile of iclaprim strongly supports its potential as a new treatment option for patients who have acquired serious infections caused by MRSA," said Dennis L. Stevens, MD, PhD, Veterans Affairs Medical Center, Boise, Idaho. "With rates of MRSA increasing and effectiveness of some current antibiotics declining, it is important to identify effective alternative treatments for these infections."

The results presented at the ICAAC/IDSA meeting were gathered from the ASSIST-1 and ASSIST-2, (Arpida's Skin and Skin Structure Infection STudy) pivotal Phase III studies involving a total of 991
'/>"/>

Contact: Dr. Jrgen Raths
41-614-179-660
Zeno Group
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. PTC124 shows activity in cystic fibrosis; Phase 2 proof-of-concept data published in Lancet
2. Improved foam for varicose veins found to be safe in preliminary results from phase II trial
3. Moms obesity during conception phase may set the stage for offsprings obesity risk
4. Liquid crystal phases of tiny DNA molecules point up new scenario for first life on Earth
5. HGS announces positive Phase 2 LymphoStat-B at ACR meeting
6. Phase 2 of Singapores Biomedical Sciences Initiative gains momentum for clinical research
7. CABI helps phase out dangerous pesticide in EU
8. SinuNase Phase 3 show almost 100 percent of chronic sinusitis cases are from fungal-induced inflamma
9. New test promises quicker, more accurate evaluation for cystic fibrosis patients
10. How eating fruit and vegetables can improve cancer patients response to chemotherapy
11. UCSF Fresno leading-edge study lends hope to emphysema patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... 27, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market, announces that ... customers the first week of May, 2015 and will ... May. Gino Pereira , Chief ... the company as Wocket® enters the consumer market. We ...
(Date:4/21/2015)... Canada , April 21, 2015 ... and evolving government policies are boosting access control systems ... According to a recently published report by ... Opportunities, 2020 ", the access control systems market in ... nearly USD1.2 billion by 2020.The access control systems market ...
(Date:4/20/2015)... The announcement comes as demand ... Management (GRM), Ireland,s foremost records management ... built up an impressive track record of clients within the ... the records management sector in Dubai . ... staffbase and employ a further eight staff members at its ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3
... years ago about the time early human tribes were ... called Neodenticula seminae went extinct in the North ... resident again, having drifted from the Pacific through the Arctic ... The melting Arctic has opened a Northwest Passage across the ...
... Office of Naval Research (ONR) Global is reaching ... members at MAST Europe 2011, June 27-29, in ... technology inventions and showcasing the organization,s efforts. ... leaders from more than 40 countries to discuss ...
... of vitamins and minerals to the human diet globally ... to a new study published in the international online ... was carried out by an interdisciplinary research team, comprised ... the Leuphana University of Lneburg, the University of Berlin ...
Cached Biology News:Prodigal plankton species makes first known migration from Pacific to Atlantic via Pole 2Prodigal plankton species makes first known migration from Pacific to Atlantic via Pole 3Prodigal plankton species makes first known migration from Pacific to Atlantic via Pole 4Prodigal plankton species makes first known migration from Pacific to Atlantic via Pole 5Prodigal plankton species makes first known migration from Pacific to Atlantic via Pole 6Office of Naval Research Global connecting with international naval community at MAST Europe 2011 2Pollinators make critical contribution to healthy diets 2
(Date:5/1/2015)... May 1, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... announced that it has priced an underwritten registered offering ... price of $9.00 per share, and granted the underwriters ... to an additional 585,000 shares of its common stock. ... million.  The offering is expected to close on May 6, ...
(Date:5/1/2015)... , May 1, 2015 Albany Molecular Research ... William S. Marth , AMRI,s President and Chief Executive ... Lynch 2015 Health Care Conference on Wednesday, May 13, ... audio webcast of the presentation can be accessed at ... The webcast will be archived for 90 ...
(Date:4/30/2015)... April 30, 2015   Tamir Biotechnology , a ... update on its Ebola antiviral therapy program. ... TMR004, is currently being evaluated and considered by a ... against Ebola. During the first quarter of 2015, the ... To Accelerate The Evaluation of Potential Treatments and Vaccines ...
(Date:4/30/2015)... 2015 The following is an open letter sent ... Cord Blood Corp (NYSE: CO ) from Jayhawk Capital. ... independent directors of China Cord Blood Corp (" China Cord ... per share from Golden Meditech Holdings Co Ltd ("Golden Med"). ... greatly benefit Golden Med and Mr. Kam, the Chairman of ...
Breaking Biology Technology:BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 3AMRI to Present at the Bank of America Merrill Lynch 2015 Health Care Conference 2Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 2Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 4April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 2April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 3April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 4April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 5
... ValGenesis, Inc., a world-class provider of Validation Lifecycle ... ValGenesis Suite 2.5 has achieved SAP certification as ... this certified integration status deepens ValGenesis, active and ... SAP Integration and Certification Center (SAP ICC) has ...
... BioLife Solutions , Inc. (OTCBB: BLFS), a leading ... hypothermic storage and cryopreservation freeze ... that TRANSFUSION , the foremost publication in ... has published a peer-reviewed journal article reporting positive ...
... Inspired Engineering at Harvard University have developed a robotic ... specific cell targets within a complex mixture of cell ... cancer cells to self-destruct. Inspired by the mechanics of ... day be used to program immune responses to treat ...
Cached Biology Technology:ValGenesis Suite 2.5 Certified by SAP as Powered by SAP NetWeaver® 2ValGenesis Suite 2.5 Certified by SAP as Powered by SAP NetWeaver® 3Improved Cord Blood Processing Research on BioLife Solutions CryoStor® Published in TRANSFUSION 2Improved Cord Blood Processing Research on BioLife Solutions CryoStor® Published in TRANSFUSION 3Improved Cord Blood Processing Research on BioLife Solutions CryoStor® Published in TRANSFUSION 4Harvard's Wyss Institute develops DNA nanorobot to trigger targeted therapeutic responses 2Harvard's Wyss Institute develops DNA nanorobot to trigger targeted therapeutic responses 3